Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
33.45
-0.06 (-0.18%)
Dec 5, 2025, 4:00 PM EST - Market closed
Spyre Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 64.9 | 89.42 | 188.89 | 34.86 | 15.14 | 90.1 | Upgrade
|
| Short-Term Investments | 421.3 | 513.67 | 150.38 | 20.85 | 77.99 | 56.18 | Upgrade
|
| Cash & Short-Term Investments | 486.2 | 603.09 | 339.28 | 55.71 | 93.13 | 146.27 | Upgrade
|
| Cash Growth | 17.38% | 77.76% | 509.00% | -40.18% | -36.33% | 103.30% | Upgrade
|
| Other Receivables | 3.6 | - | - | 0.38 | 0.82 | - | Upgrade
|
| Receivables | 3.6 | - | - | 0.38 | 0.82 | - | Upgrade
|
| Prepaid Expenses | 11.81 | 5.39 | 2.25 | 6.17 | 4.95 | 3.52 | Upgrade
|
| Other Current Assets | 3 | - | - | - | - | - | Upgrade
|
| Total Current Assets | 504.6 | 608.47 | 341.53 | 62.26 | 98.89 | 149.79 | Upgrade
|
| Property, Plant & Equipment | - | - | - | 7.25 | 9.15 | 9.94 | Upgrade
|
| Other Long-Term Assets | - | 0.01 | 0.33 | 1.64 | 1.88 | 1.89 | Upgrade
|
| Total Assets | 504.6 | 608.48 | 341.86 | 71.14 | 109.93 | 161.62 | Upgrade
|
| Accounts Payable | 7.46 | 0.67 | 0.9 | 0.68 | 3.32 | 2.25 | Upgrade
|
| Accrued Expenses | 23.83 | 27.31 | 29.2 | 12.82 | 13.25 | 13.41 | Upgrade
|
| Current Portion of Leases | - | - | - | 0.64 | 0.85 | 0.35 | Upgrade
|
| Current Unearned Revenue | - | - | - | 0.52 | 2.36 | - | Upgrade
|
| Other Current Liabilities | 14.99 | 26.08 | 1.88 | - | 0.37 | 0.44 | Upgrade
|
| Total Current Liabilities | 46.27 | 54.06 | 31.98 | 14.66 | 20.14 | 16.44 | Upgrade
|
| Long-Term Leases | - | - | - | 4 | 4.62 | 5.17 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 2.18 | 1.22 | - | Upgrade
|
| Other Long-Term Liabilities | 3.23 | 36.62 | 125.87 | - | - | 0.17 | Upgrade
|
| Total Liabilities | 49.5 | 90.68 | 157.84 | 20.84 | 25.99 | 21.79 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 1,364 | 1,334 | 763.19 | 475.97 | 425.77 | 415.82 | Upgrade
|
| Retained Earnings | -1,065 | -972.43 | -764.41 | -425.62 | -341.81 | -276.01 | Upgrade
|
| Comprehensive Income & Other | 0.79 | 0.18 | 0.3 | -0.05 | -0.02 | 0.01 | Upgrade
|
| Total Common Equity | 299.28 | 361.98 | -0.91 | 50.31 | 83.94 | 139.83 | Upgrade
|
| Shareholders' Equity | 455.1 | 517.8 | 184.02 | 50.31 | 83.94 | 139.83 | Upgrade
|
| Total Liabilities & Equity | 504.6 | 608.48 | 341.86 | 71.14 | 109.93 | 161.62 | Upgrade
|
| Total Debt | - | - | - | 4.65 | 5.48 | 5.52 | Upgrade
|
| Net Cash (Debt) | 486.2 | 603.09 | 339.28 | 51.07 | 87.65 | 140.75 | Upgrade
|
| Net Cash Growth | 17.38% | 77.76% | 564.39% | -41.74% | -37.73% | 110.62% | Upgrade
|
| Net Cash Per Share | 8.23 | 12.82 | 49.19 | 15.15 | 33.33 | 65.93 | Upgrade
|
| Filing Date Shares Outstanding | 77.59 | 60.28 | 36.15 | 2.62 | 1.97 | 1.92 | Upgrade
|
| Total Common Shares Outstanding | 60.47 | 60.26 | 36.06 | 2.61 | 1.97 | 1.92 | Upgrade
|
| Working Capital | 458.33 | 554.41 | 309.55 | 47.6 | 78.75 | 133.35 | Upgrade
|
| Book Value Per Share | 4.95 | 6.01 | -0.03 | 19.24 | 42.52 | 72.89 | Upgrade
|
| Tangible Book Value | 299.28 | 361.98 | -0.91 | 50.31 | 83.94 | 139.83 | Upgrade
|
| Tangible Book Value Per Share | 4.95 | 6.01 | -0.03 | 19.24 | 42.52 | 72.89 | Upgrade
|
| Machinery | - | - | - | 2.85 | 2.82 | 2.72 | Upgrade
|
| Leasehold Improvements | - | - | - | 4.39 | 4.39 | 4.77 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.